Live Analyst Rating Changes 20533 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Gil Blum
NDM

Gil Blum

Needham
Wall Street Analyst
★★★★☆
#759
on 13Foresight · ranked by our own returns
59%
Success Rate
+9.2%
Average Return
30 of 51 calls profitable · +5.8% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 59% of Gil Blum's ratings turned a profit when each position was held for 1 year — averaging +9.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

147 Buy 24 Hold 9 Sell
Gil's Stock Coverage 28 ratings · 2026-08-08
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
ARTV
Artiva Biotherapeutics, Inc.
 Aug 07, 2026 BUY Strong Buy
+165.6% avg upside
7 analysts
$41.00
254.07% Upside
 +0.0% ·
LYEL
Lyell Immunopharma
 Aug 07, 2026 BUY Strong Buy
+91.9% avg upside
12 analysts
$44.00
209.60% Upside
 · ·
SLDB
Solid Biosciences
 Aug 07, 2026 BUY Strong Buy
+87.8% avg upside
23 analysts
$19.00
118.05% Upside
 · ·
SRPT
Sarepta Therapeutics
 Aug 06, 2026 SELL Buy
+255.4% avg upside
49 analysts
 — +1.2% ·
IMCR
Immunocore Holdings
 Aug 06, 2026 BUY Strong Buy
+88.9% avg upside
22 analysts
$75.00
117.44% Upside
 -1.5% ·
RNAC
Cartesian Therapeutics
 Aug 06, 2026 BUY Strong Buy
+258.4% avg upside
19 analysts
$40.00
356.53% Upside
 +0.5% ·
RXRX
Recursion Pharmaceuticals
 Aug 05, 2026 BUY Buy
+147.2% avg upside
12 analysts
$8.00
151.49% Upside
 +1.6% ·
GERN
Geron
 Aug 05, 2026 BUY Strong Buy
+184.9% avg upside
19 analysts
$4.00
154.85% Upside
 -9.2% ·
NRIX
Nurix Therapeutics
 Aug 04, 2026 BUY Strong Buy
+26.2% avg upside
28 analysts
$34.00
34.78% Upside
 +2.1% ·
CRSP
Crispr Therapeutics AG
 Aug 04, 2026 BUY Buy
+43.2% avg upside
41 analysts
$82.00
58.75% Upside
 +0.9% ·
AUTL
Autolus Therapeutics
 Aug 03, 2026 BUY Strong Buy
+417.2% avg upside
16 analysts
$10.00
399.94% Upside
 +15.9% ·
IMMX
Immix Biopharma
 Jul 22, 2026 BUY Strong Buy
+86.9% avg upside
9 analysts
$21.00
108.65% Upside
 -11.6% ·
CELC
Celcuity
 Jul 15, 2026 BUY Strong Buy
+34.5% avg upside
16 analysts
$157.00
68.30% Upside
 +1.4% ·
FATE
Fate Therapeutics
 Jul 10, 2026 HOLD Buy
+343.8% avg upside
31 analysts
 — -17.7% ·
TSHA
Taysha Gene Therapies
 Jul 01, 2026 BUY Strong Buy
+114.6% avg upside
21 analysts
$12.00
89.31% Upside
 -3.6% ·
ABSI
AbSci
 Jun 24, 2026 BUY Strong Buy
+36.1% avg upside
18 analysts
$11.00
32.54% Upside
 -16.6% ·
TCRX
TScan Therapeutics
 Jun 23, 2026 BUY Strong Buy
+976.2% avg upside
12 analysts
$6.00
686.18% Upside
 -13.6% ·
NKTX
Nkarta
 May 13, 2026 BUY Strong Buy
+687.3% avg upside
16 analysts
$11.00
380.31% Upside
 -21.2% ·
MREO
Mereo Biopharma Group Plc
 May 12, 2026 BUY Strong Buy
+1185.6% avg upside
11 analysts
$3.00
880.74% Upside
 +30.1% ·
RCKT
Rocket Pharmaceuticals
 May 08, 2026 HOLD Buy
+357.2% avg upside
29 analysts
 — -3.9% ·
STTK
Shattuck Labs
 Nov 07, 2025 HOLD Strong Buy
+202.5% avg upside
15 analysts
 — +261.6% ·
NBP
NovaBridge Biosciences
 Oct 24, 2025 HOLD Strong Buy
+1121.1% avg upside
14 analysts
 — -58.5% ·
NXTC
NextCure
 Dec 27, 2024 HOLD Buy
+214.3% avg upside
10 analysts
 — +29.8% ·
GB:0DPB
Bavarian Nordic AS
 Feb 16, 2023 BUY Strong Buy
+100.7% avg upside
5 analysts
$371.00
112.24% Upside
 -30.3% ·
TECX
Tectonic Therapeutic
 Dec 07, 2022 BUY Strong Buy
+82.5% avg upside
24 analysts
$6.00
80.19% Downside
 +78.2% ·
SYRE
Spyre Therapeutics
 Aug 25, 2022 HOLD Strong Buy
-12.8% avg upside
23 analysts
 — +0.0% ·
ATHXQ
Athersys
 Jun 03, 2022 HOLD Buy
+2996428471.4% avg upside
8 analysts
 — · ·
GNCAQ
Genocea Biosciences
 Apr 06, 2022 BUY Strong Buy
+573999900.0% avg upside
10 analysts
$6.00
599999899.97% Upside
 · ·
🔒 23 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Gil Blum — Frequently Asked Questions
How accurate are Gil Blum's stock ratings?
Based on the calls 13Foresight could measure, about 59% of Gil's ratings were profitable over a one-year hold, with an average return of +9.2% per rating, or +5.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Gil ranked on 13Foresight?
Gil Blum is currently ranked #759 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Gil cover?
Gil most recently has ratings on ARTV, LYEL, SLDB, SRPT, IMCR, RNAC, RXRX, GERN, NRIX, CRSP, AUTL, IMMX and 16 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.